ArticleESMO open2017

Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.

Jan Norum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.